Tag - LYRA

Developments

Lyra restarts Phase 3 trial in chronic rhinosinusitis

Lyra Therapeutics (NASDAQ:LYRA) resumed screening and enrollment in ENLIGHTEN II, its second Phase 3 clinical trial of LYR-210 in patients with chronic rhinosinusitis (CRS). LYR-210 is a bioresorbable nasal implant...

April 25, 2023

Markets

Cantor starts Lyra Therapeutics at OW; PT $15

Cantor Fitzgerald initiated coverage of Lyra Therapeutics (NASDAQ:LYRA) with an “overweight” rating and price target of $15. The stock closed at $6.07 on May 23. Lyra is a clinical-stage company developing medicines...

May 24, 2022

Markets

Analysts start coverage of Lyra Therapeutics at buy, OP

Analysts for BTIG and William Blair launched coverage of Lyra Therapeutics (NASDAQ:LYRA) with “buy” and “outperform” ratings, respectively. Lyra is developing a novel drug delivery platform for ear, nose and throat...

May 26, 2020

Tag - LYRA

Lyra restarts Phase 3 trial in chronic rhinosinusitis

Cantor starts Lyra Therapeutics at OW; PT $15

Analysts start coverage of Lyra Therapeutics at buy, OP

General

More